NetApp and the 49ers Foundation Launch Data Science Education Partnership
15.10.2025 14:00:00 CEST | Business Wire | Press Release
NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, and the 49ers Foundation, the largest team foundation in the NFL, today announced a multi-year partnership to provide data science education to high school students in the San Francisco Bay Area. The 49ers EDU Data Analytics Lessons Series seeks to inspire and equip the next generation of tech leaders with essential skills in data science and introduce students to career opportunities in technology.
The partnership will enable NetApp and the 49ers Foundation to utilize the unique setting of Levi’s® Stadium to provide immersive educational experiences. This collaboration is part of the 49ers EDU STEAM education program and builds upon its impactful history of educating over a half a million students in the Bay Area and beyond through digital and in-person programming. 49ers EDU educators will lead all lessons part of the Data Analytics Lessons Series, while NetApp volunteers will support students in technology career exploration.
“NetApp is committed to expanding access to data and AI education,” said George Kurian, CEO of NetApp. “Through our partnership with the 49ers Foundation, we’re providing students with the real-world experience and skill-building to thrive in a world shaped by data and AI. By providing students with hands-on opportunities in data analytics, we hope to inspire the next generation of technology leaders.”
The Data Analytics Lessons Series will teach students about data storage, cloud integration, data security, and performance optimization, all of which are crucial for managing data in real-world scenarios, including gameday operations at the stadium.
“After celebrating ten years of 49ers EDU earlier this year, we’re excited to partner with NetApp to integrate data science into 49ers EDU programming using their latest and best technologies,” said Justin Prettyman, Vice President, Philanthropy, Executive Director, 49ers Foundation. “NetApp’s commitment to serving the next generation makes them an impactful addition to our growing 49ers Foundation family. We can’t wait to partner with them to educate the world’s future technology leaders and innovators.”
“Being in the heart of Silicon Valley, we have a deep connection with technology and feel a responsibility to educate the next generation about how intertwined sports and technology are,” said Costa Kladianos, 49ers Executive Vice President of Technology. “NetApp allows us to collect, store, analyze, and utilize vast amounts of data, which ultimately allows us to have the world-class fan experience that Levi’s® Stadium is known for. We can’t wait to use our partnership to educate Bay Area youth.”
Additionally, at NetApp INSIGHT 2025, the 49ers Foundation will receive a NetApp Customer Social Impact Award for its leadership in data science education through the 49ers EDU program.
To learn more about the partnership between NetApp and the 49ers Foundation, visit 49ers.com/EDU.
Additional Resources
- 49ers and NetApp Data Analytics Education Partnership Video
- San Francisco 49ers and NetApp: Powered by Intelligent Data Infrastructure
- 49ers EDU Data Analytics Lessons Photo Album
- San Francisco 49ers and NetApp Team Up to Elevate Operations and Fan Experience
- 49ers Announce First Group of Speakers to Participate in the Horizon Summit
- NFL Names NetApp the Official Intelligent Data Infrastructure Partner
About the 49ers Foundation
For over 30 years, the 49ers Foundation has harnessed football to educate and empower youth in the Bay Area and beyond through collective and innovative community-focused strategies. From award-winning STEAM education and nationally recognized youth football programs, to impactful community partnerships with leading nonprofits, the 49ers Foundation is tirelessly dedicated to inspiring the confidence and collaboration youth need to tackle what is possible. Since 1991, the 49ers Foundation has invested more than $70 million back into historically underserved Bay Area communities in support of its commitment to remain faithful to the next generation. Visit 49ers.com/foundation.
About NetApp
For more than three decades, NetApp has helped the world’s leading organizations navigate change – from the rise of enterprise storage to the intelligent era defined by data and AI. Today, NetApp is the Intelligent Data Infrastructure company, helping customers turn data into a catalyst for innovation, resilience, and growth.
At the heart of that infrastructure is the NetApp data platform – the unified, enterprise-grade, intelligent foundation that connects, protects, and activates data across every cloud, workload, and environment. Built on the proven power of NetApp ONTAP, our leading data management software and OS, and enhanced by automation through the AI Data Engine and AFX, it delivers observability, resilience, and intelligence at scale.
Disaggregated by design, the NetApp data platform separates storage, services, and control so enterprises can modernize faster, scale efficiently, and innovate without lock-in. As the only enterprise storage platform natively embedded in the world’s largest clouds, it gives organizations the freedom to run any workload anywhere with consistent performance, governance, and protection.
With NetApp, data is always ready – ready to defend against threats, ready to power AI, and ready to drive the next breakthrough. That’s why the world’s most forward-thinking enterprises trust NetApp to turn intelligence into advantage.
Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251015680963/en/
Contacts
Media Contacts
Jacob Fill, San Francisco 49ers
Jacob.Fill@49ers.com | 408.466.7212
Kenya Hayes, NetApp
Kenya.Hayes@netapp.com
Investor Contact
Kris Newton, NetApp
Kris.Newton@netapp.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom